Targeted therapy for triple-negative breast cancer: Where are we?

被引：82
作者：
Duffy, Michael J. [1 ,2 ]
McGowan, Patricia M. [2 ]
Crown, John [3 ,4 ]
机构：
[1] St Vincents Univ Hosp, UCD Clin Res Ctr, Dublin 4, Ireland
[2] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, UCD Sch Med & Med Sci, Dublin 4, Ireland
[3] Dublin City Univ, Natl Inst Cellular Biotechnol, Dublin 9, Ireland
[4] St Vincents Univ Hosp, Dept Med Oncol, Dublin 4, Ireland
来源：
INTERNATIONAL JOURNAL OF CANCER | 2012年 / 131卷 / 11期
基金：
爱尔兰科学基金会;
关键词：
triple-negative breast cancer; biomarkers; predictive markers; PARP; GROWTH-FACTOR RECEPTOR; POLY(ADP-RIBOSE) POLYMERASE INHIBITION; CELL-LINES; PTEN LOSS; MOLECULAR CHARACTERIZATION; MUTANT-CELLS; OPEN-LABEL; BASAL; DASATINIB; TUMOR;
D O I：
10.1002/ijc.27632
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Breast cancers that are negative for estrogen receptor (ER), progesterone receptors (PR) and HER2, using standard clinical assays, have been dubbed triple-negative (TN). Unlike other molecular subtypes of invasive breast cancer, validated targeted therapies are currently unavailable for patients with TN breast cancer. Preclinical studies however, have identified several potential targets such as epidermal growth factor receptor (EGFR), SRC, MET and poly ADP ribose polymerase 1/2 (PARP1/2). Because of tumor heterogeneity, it is unlikely that any single targeted therapy will be efficacious in all patients with TN breast cancer. The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy.
引用
收藏
页码：2471 / 2477
页数：7
相关论文
共 91 条
[11]   Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].
Bryant, HE ;
Schultz, N ;
Thomas, HD ;
Parker, KM ;
Flower, D ;
Lopez, E ;
Kyle, S ;
Meuth, M ;
Curtin, NJ ;
Helleday, T .
NATURE, 2005, 434 (7035) :913-917
[12]   C-MET as a new therapeutic target for the development of novel anticancer drugs [J].
Canadas, Israel ;
Rojo, Federico ;
Arumi-Uria, Montserrat ;
Rovira, Ana ;
Albanell, Joan ;
Arriola, Edurne .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (04) :253-260
[13]  
Carey L., 2010, ONCOLOGIST S, V15, P8
[14]   TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer [J].
Carey, L. A. ;
Rugo, H. S. ;
Marcom, P. K. ;
Irvin, W., Jr. ;
Ferraro, M. ;
Burrows, E. ;
He, X. ;
Perou, C. M. ;
Winer, E. P. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[15]   Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors [J].
Carlos Montero, Juan ;
Seoane, Samuel ;
Ocana, Alberto ;
Pandiella, Atanasio .
CLINICAL CANCER RESEARCH, 2011, 17 (17) :5546-5552
[16]   Targeting the HGF/Met signalling pathway in cancer [J].
Cecchi, Fabiola ;
Rabe, Daniel C. ;
Bottaro, Donald P. .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (07) :1260-1270
[17]   Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin [J].
Ceppi, Paolo ;
Papotti, Mauro ;
Monica, Valentina ;
Lo Iacono, Marco ;
Saviozzi, Silvia ;
Pautasso, Marisa ;
Novello, Silvia ;
Mussino, Stefano ;
Bracco, Enrico ;
Volante, Marco ;
Scagliotti, Giorgio V. .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (11) :3066-3074
[18]   Gene expression profiling of breast cell lines identifies potential new basal markers [J].
Charafe-Jauffret, E ;
Ginestier, C ;
Monville, F ;
Finetti, P ;
Adélaïde, J ;
Cervera, N ;
Fekairi, S ;
Xerri, L ;
Jacquemier, J ;
Birnbaum, D ;
Bertucci, F .
ONCOGENE, 2006, 25 (15) :2273-2284
[19]   Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].
Chung, KY ;
Shia, J ;
Kemeny, NE ;
Shah, M ;
Schwartz, GK ;
Tse, A ;
Hamilton, A ;
Pan, D ;
Schrag, D ;
Schwartz, L ;
Klimstra, DS ;
Fridman, D ;
Kelsen, DP ;
Saltz, LB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810
[20]   Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer [J].
Corkery, B. ;
Crown, J. ;
Clynes, M. ;
O'Donovan, N. .
ANNALS OF ONCOLOGY, 2009, 20 (05) :862-867
12345678910